<DOC>
	<DOCNO>NCT02502578</DOCNO>
	<brief_summary>The purpose study assess safety examine index efficacy repeat dose CNT-01 patient idiopathic triglyceride deposit cardiomyovasculopathy .</brief_summary>
	<brief_title>Safety Study CNT-01 Patients With Idiopathic TGCV</brief_title>
	<detailed_description />
	<criteria>Have definite diagnosis idiopathic triglyceride deposit cardiomyovasculopathy After receive sufficient explanation upon participation study , full understanding , patient obtain write informed consent patient More 20 year old time inform consent Is able oral intake Must willing comply protocolrequired examination BMIPP myocardial scintigraphy Have diabetic ketoacidosis Have malignancy treat anticancer drug anticipate survival less three year Female pregnant lactating Is able agree use intrauterine device , oral contraceptive , condom sexual intercourse start take investigational product 30 day end study Have New York Heart Association functional classification IV Have know history drug dependence Is allergic component investigational product Is allergic BMIPP iodine Have know history clinically significant drug allergy Have severe liver dysfunction ( Child classification B C ) Participated clinical study within past 3 month receive investigational agent include placebo Being treat diet contain medium chain fatty acid Is consider unfit study Investigator 's medical decision</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Triglyceride Deposit Cardiomyovasculopathy</keyword>
</DOC>